Anatara Lifesciences Ltd
Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in Australia. The company's products include Gastrointestinal ReProgramming, a multi-component, multi-coated medicine designed to address underlying factors associated with chronic gastrointestinal conditions, such as irritable bowel syndrome and inflammat… Read more
Anatara Lifesciences Ltd (ANR) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -2.561x
Based on the latest financial reports, Anatara Lifesciences Ltd (ANR) has a cash flow conversion efficiency ratio of -2.561x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-1.37 Million) by net assets (AU$535.97K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Anatara Lifesciences Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how Anatara Lifesciences Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Anatara Lifesciences Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Anatara Lifesciences Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nordea Invest Aktier II KL 1
CO:NDIAKTIIKL1
|
N/A |
|
Zamp S.A.
SA:ZAMP3
|
-0.066x |
|
Findev Inc
PINK:TNSGF
|
0.000x |
|
Hana Financial Group Inc.
KQ:086790
|
N/A |
|
AVILA ENERGY CORP.
F:6HQ0
|
N/A |
|
Happy Creek Minerals Ltd
PINK:HPYCF
|
-0.016x |
|
Scryb Inc
PINK:SCYRF
|
-0.088x |
|
PT Champion Pacific Indonesia Tbk
STU:IUD
|
0.051x |
Annual Cash Flow Conversion Efficiency for Anatara Lifesciences Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of Anatara Lifesciences Ltd from 2013 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | AU$535.97K | AU$-2.27 Million | -4.239x | -363.73% |
| 2024-06-30 | AU$1.36 Million | AU$-1.25 Million | -0.914x | +62.57% |
| 2023-06-30 | AU$924.54K | AU$-2.26 Million | -2.442x | -49.22% |
| 2022-06-30 | AU$1.36 Million | AU$-2.23 Million | -1.637x | -198.86% |
| 2021-06-30 | AU$3.83 Million | AU$-2.10 Million | -0.548x | +42.59% |
| 2020-06-30 | AU$2.86 Million | AU$-2.72 Million | -0.954x | -152.17% |
| 2019-06-30 | AU$5.92 Million | AU$-2.24 Million | -0.378x | +2.02% |
| 2018-06-30 | AU$8.59 Million | AU$-3.32 Million | -0.386x | -61.22% |
| 2017-06-30 | AU$12.02 Million | AU$-2.88 Million | -0.239x | -1050.92% |
| 2016-06-30 | AU$13.48 Million | AU$-280.37K | -0.021x | +94.08% |
| 2015-06-30 | AU$5.48 Million | AU$-1.92 Million | -0.351x | -296.93% |
| 2014-06-30 | AU$7.23 Million | AU$-639.27K | -0.088x | -114.01% |
| 2013-06-30 | AU$-280.65K | AU$-177.22K | 0.631x | -- |